Member Info for Saxondale

Yes Ques there is a lot of little bits of detail in the presentation that needs a few reads to pick up on .
Interesting to see the Clevegen roadmap laid out , with the Matins running as a monotherapy trial , then combination trials planned to kick in through 2021-2022 .
The topline data from the expansion cohorts is going to be the crunch news - Q4 this year .
Surely that will be when some partnerships will be announced , as although Faron are well funded , running phase 3 trials on 10 different tumour types will require mega bucks and some kind of external deal .
Hence Markkus prediction of shareholder value gains in this Q4 .
He was almost shaking with glee when he last talked of the interest in the Clevegen program now by potential partners .

Hard to predict if they plan to continue with Traumakine as 100% owned by themselves . They certainly seem to have to manufacturing budget in place , but in 2018 before you know what happened , they were talking to companies about partnering , and immediately went back talking to them once they had some answers .
But who knows , the stakes are a lot higher now , and the rewards for a viable ARDS treatment are unbelievably higher than they were 9 months ago .
As our friend Zen used to say alot , the entry price for a partner has just been going up and up .

And the fundamental status of the number of shares ( 47m) , and the free float ( 25m) make for a valuable share if things go the way we hope .

This story popped up about a month ago somewhere , about the two brothers getting ill , and scientists mooting a genetic link .
Looks like thats the case , and to be tied in with the interferon response makes its even more relevant for us .
Then add in Farons discovery that certain people hold a single nucleotide polymorphism in their genetic makeup that make them more responsive to Interferon treatment . This allows doctors to decide ( after a quick PCR gene test ) who may benefit the most from Interferon treatment ( on average 30-35% of Caucasians , 40-45% of Africans and 10% of Asians )
Then add in what they now know of the role of corticosteroids when mixed with Interferon treatment , and we are in a far better position in understanding the effective role of this treatment .

The 2018 RNS explaining it -
https://otp.tools.investis.com/clients/uk/faron/rns/regulatory-story.aspx?cid=2223&newsid=1214524

The 2019 patent -
https://patents.justia.com/patent/20200199677

By narrowing down and targeting the groups who they expect to be most receptive , the statistical effectiveness of Traumakine should just keep on rising .

The fact that we are still running in Solidarity , and have been promoted to a mono therapy domain must surely derisk the chance of total failure to zero . Add in the fact we are in the same position with Remap , things are boding very well .
Add in that now we have manufacturing partnerships , and Govts and institutions throwing money at us , and long term up scaling plans for commercial production of a patented freeze dried form of Interferon .

Surely Q4 will be the £10 quarter ( for starters )
It will be well deserved by the company , and for the positive and loyal shareholders .
And that will be just the start of the next step of the journey .

Its a real possibility now that we get a Clevegen Matins update and a Traumakine trial update in the same month or even week .

Exciting times ahead

Been away for a few days , just got to read the presentation . Looking slicker for a start .
So Q4 we get the update on all the 10 cohorts with Matins , and the Solidarity update .
Good to see some Hibiscus detail , although I note they say that it is still in the planning and although they expect to run it , things may change ( from this I assume they mean if Solidarity results are that good - then perhaps they won't have to run it , or not at the scale they are planning at present . Faron are obviously paying for Hibiscus , and its a big trial , 450 patients .)

Also good to see they have more IP protection granted for Traumakine , and more for Clevegen with more to come .

Overall , a really positive report with some big steps made , and a clear vision of where they are going .
Well funded , everything progressing well , manufacturers set up , and multiple shots on goal coming up as they say themselves !

So it looks like our secret weapon now has an official name - Haematokine

Another important area - blood cancers - lymphoma and leukemia , and again one where doesn't look like there is much in the way of treatments - chemo , radiotherapy and stem cell transplants .

But I'm not 100% clear if this is the same secret weapon we were talking about in March .

Back then they RNS'd that they had a new patent and ownership of an A0c3 inhibitor , and blurb about vascular diseases .
I guess it is , as the pipeline shows H as a A0c3 inhibitor , but maybe we will see more pipeline applications appearing , as they apply it to more illnesses ( I had vascular diseases down as inflammation and diabetes etc , not leaukemia and lymphoma cancers ? )

At least we know with Faron that they file their patents well , and will have all the bases covered .

Also noticed that they now have Clevegen showing up in preclinical studies for hematological malignancies , in addition to the solid tumor studies . So not only is is being tried in 10 different solid tumor cancers , it is now obviously showing potential in blood cancers .
Talk about one ring to rule them all !

Traumakine - now showing the REMAP and Solidarity trials , and Hibiscus in the USA awaiting initiation.
R & S trials both showing as PHASE 3 - so any positive results from them could and should lead straight to market authorisation , or EUA at least whilst Hibiscus gets carried out .

Its been a long time since we heard Markku talking excitedly ( well as excited as you can get being Finnish ) about the manufacturing ramping up to commercial volume and being ready to make the next step .

As usual - lots of news overdue , and we are sure to get some on or before Thursday 24th .

Maybe there is something in that detail that we are missing , i.e that is worth or needs to be RNS'd .
Either way , its nice that the MATINS trial is both ongoing to schedule and still being seen as promising by investigators .
And SP is holding well and rising slightly .

very good RNS - probably not much chance of a last top up under 20 now .
Still holding all the shares I had pre suspension ( and more added )
Looks like our day is coming .

With the looming economic depression on the way , how many companies can expect their sales and profits to be so high running into the next year ? Not many I think .
M&A to strengthen the business and increase shareholder value .
Any drop I will be adding more thanks

Thanks Q&H for the conference reporting .
When I used to be in sales I was always told - sell them the sizzle , not the sausage .
Well it looks like Markku just gives you the sausage , and it's up to you to imagine the sizzle.

He is doing his presentation at 4pm our time , so it would need something RNS'd if hes dropping something important there .

Nothing in the past has ever been dropped as a bombshell at any of these investor meetings ( apart from the teasing news of the A0C3 inhibitor - and even that was vague )

The big news is either T related , which could come any time , and probably won't be timing that Faron will choose , or C news , which is something they can announce at a time that suits them - I'm thinking the 24th .

Either way , Faron shareholders are all certainly sitting on their hands , as our GGP comrades always seem to be advising us to do lol

Funny old share thats for sure.
I'm in GGP & EUA and spend hours reading pages of complete waffle in order to glean odd bits of useful info from the few knowledgeable posters. The price of success maybe ?
Here at Faron they make it easy for you - just read the RNS's and sit back :-)

23.4

Important bits I took from that article :
Using a cell line model, we found that beta interferon (IFN-ß) strongly upregulated expression of canonical antiviral ISGs, as well as ACE2 at the mRNA and cell surface protein levels. Strikingly, IFN-?1 upregulated antiviral ISGs, but ACE2 mRNA was only marginally elevated and did not lead to detectably increased ACE2 protein at the cell surface. IFN-? induced the weakest ISG response but clearly enhanced surface expression of ACE2. Importantly, all IFN types inhibited SARS-CoV-2 replication in a dose-dependent manner, and IFN-ß and IFN-?1 exhibited potent antiviral activity in primary human bronchial epithelial cells.

and :
all the IFNs limited SARS-CoV-2 replication, suggesting that their antiviral actions can counterbalance increased ACE2.

IFN Beta1a showed best results against the other 2 types in their observations .

Another good news story thanks

I remember selling my few shares at REDX a while ago - because the share seemed so boring - nobody on the BB making any comments , the CEO was dull as dishwater , what a yawnfest . Sold at 7 or 8p I think . Just checked , its at 70p today .
Sometimes is the quiet ones that make you money .
However , I still stand by my comment that it was a yawnfest (b/stards ! )

Posted today on REMAP-CAP website
https://www.remapcap.org/covid19publications

Basically they fall in line with WHO recommendation that steroids are a benefit to those who have not progressed into the more severe category of needing ventilation assistance .
Nothing about any other treatment .
The optimist would assume that the Interferon beta therapy would be something used when patients are into that severe category , as Markku mentioned in one interview relating to REMAP - that once the patient is into that severe lung condition and is so severe that they need to be put on a ventilator , there is no other treatment available other than Interferon beta 1a.
Of the 614 patients recruited in the period they are talking about , 403 were administered into a steroid domain . So 211 patients were treated in non steroid ( ie Faron friendly) domains .
That was only up until June17th - when they halted the steroid part of trial
So since we have over 900 recruits as of today - that would mean a total of 497 who are in non-steroid domains - so at least plenty of possible patients for us to be used with.
Now we need the findings from the other therapies , antiviral and Immune Modulation domains to see where we fit into this .
In my opinion , this shows that steroids as an anti inflammatory show success at reducing Covid deaths and illness to a point , but we are yet to see what can help when patients move into the ARDS severity end of the spectrum .
Likewise with SNG and their nebuliser - looks to be great at the early stages when a direct hit to the lungs seems to work .

Its what happens when things go a bit pear shaped and the patient is critical , can't take a nebuliser as lung tissue is too damaged , and steroids are ineffective .

The wait continues...

You too . Can't wait until we can all start chewing over some real information . Results and updates .
Its about time we had a good meaty RNS - we deserve it !

Yes still here mate - patiently waiting with all the others lol.
I thought i'd take a step back for a few weeks , didn't want to seem like the excited kid in the back seat annoying his parents .
Not much to report either , still hoping one of my other shares goes nuts so I can have one last top up here before boom time !

Had to check in last night under the sheets , great news again !
That schematic is starting to look less like a horseshoe and more like a giant Mr Blobby !
Can't wait for the Berenberg broker note . Surely the next one will be in the 30's at least , and thats before we even get a sniff of any finds in Scally or the other areas .
Well done everyone and thanks again to the resident experts .
Happy Days

Nice to see the job is ' permanent full time '
Job for life in my opinion

After a quick read , it does seem that they are now advocating the use of steroids ( in severe and critical cases - when ventilator etc may be needed - or no ventilator is available)
However , in the conclusion , it explains that the main reason they are recommending drugs such as dexamethasone is that they are cheap and easily available - rather than less available and more expensive treatments ie such as ventilators etc .
We have to remember that the WHO is representing the vast majority of the poorer countries here with limited funds and equipment , and the bulk of whose populations will often not even have the chance to access a hospital ( India etc )
Faron have stated that they accept corticosteroids could be used in conjunction with Traumakine - just not at the same time.

You can't take away the facts that Traumakine has proven successful in trials with post hoc analysis.

Just wish they'd hurry up and get their data out on us from REMAP & Solidarity !

Hard to remember what was there before Oil , but noticed that they are recruiting in the USA now ( University of Texas ) .
Don't recall seeing that before but it may well have been there .